Intercept Pharmaceuticals Insider Luciano Adorini Sells 1,634 Shares (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) Insider Luciano Adorini sold 1,634 shares of Intercept Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $67.41, for a total value of $110,147.94. Following the sale, the insider now directly owns 6,392 shares of the company’s stock, valued at approximately $430,885. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals to $270.00 in a research note to investors on Thursday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $106.80.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 281.09% on Thursday, hitting $275.87. The stock had a trading volume of 6,840,347 shares. Intercept Pharmaceuticals has a 52-week low of $30.38 and a 52-week high of $305.00. The stock’s 50-day moving average is $66.99 and its 200-day moving average is $55.33. The company’s market cap is $5.334 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings data on Thursday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $1.14. During the same quarter last year, the company posted ($1.86) earnings per share. On average, analysts predict that Intercept Pharmaceuticals will post $-3.45 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.